Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mln
Palatin's fiscal Q1 2026 revenue reached $8.8 million, driven by a collaboration with Boehringer Ingelheim. The company reported a net income of $4.7 million, reversing last year's loss. Palatin completed an $18.2 million public offering, regaining NYSE American compliance. Future plans include IND submission and Phase 1 trial for PL7737, and mid-2026 IND filing for MC4R agonists. The FDA granted Orphan Drug Designation for leptin receptor deficiency obesity.
)
Overview
- Palatin fiscal Q1 2026 revenue rises to $8.8 mln, driven by Boehringer Ingelheim agreement
- Company reports fiscal Q1 net income of $4.7 mln, reversing a loss from last year
- Palatin completes $18.2 mln public offering, regains NYSE American compliance
Outlook
- Company plans IND submission and Phase 1 trial for PL7737 in first half of 2026
- Palatin expects mid-2026 IND filing for next-gen MC4R agonists
- Company received FDA Orphan Drug Designation for leptin receptor deficiency obesity
Result Drivers
- BOEHRINGER INGELHEIM COLLABORATION - Revenue increase attributed to Boehringer Ingelheim collaboration, including upfront payment and milestone achievement
- PUBLIC OFFERING - Successful $18.2 mln public offering strengthened balance sheet and regained NYSE American compliance
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q1 EPS $4.26
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
